Long-term outcome in heart transplant patients with pretransplant malignancies.

[1]  E. Roig,et al.  Steroid use in heart transplant patients in Spain in the current era: a multicenter survey. , 2009, Transplantation proceedings.

[2]  J. Muñiz,et al.  Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  F. Pagani,et al.  Heart and Lung Transplantation in the United States, 1997–2006 , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  M. Crespo-Leiro,et al.  Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  J. Robert.  Long-term and short-term models for studying anthracycline cardiotoxicity and protectors , 2007, Cardiovascular Toxicology.

[6]  S. Hunt.  Taking heart--cardiac transplantation past, present, and future. , 2006, The New England journal of medicine.

[7]  S. Nissen,et al.  New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. , 2006, Circulation.

[8]  J. Ladowski,et al.  Long-term follow-up of hearttransplant recipients with pre-transplant malignancies. , 2006, Texas Heart Institute journal.

[9]  H. Sollinger.  Mycophenolates in transplantation , 2004, Clinical transplantation.

[10]  M. Crespo-Leiro,et al.  Tacrolimus in heart transplantation. , 2003, Transplantation proceedings.

[11]  F. Pigula,et al.  Cardiac transplantation in survivors of lymphoma: a multi-institutional survey. , 2000, Transplantation.

[12]  R. Rodeheffer,et al.  Heart transplantation for radiation-associated end-stage heart failure , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  F. Pigula,et al.  CARDIAC TRANSPLANTATION IN SURVIVORS OF LYMPHOMA , 2000 .

[14]  U. Livi,et al.  Heart transplantation in patients with neoplastic disease. , 1998, Transplantation proceedings.

[15]  G. Tenderich,et al.  Results of heart transplantation in patients with preexisting malignancies. , 1997, The American journal of cardiology.

[16]  M. Turina,et al.  Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Oz,et al.  Orthotopic heart transplantation in patients with treated malignancies. , 1995, American Journal of Cardiology.

[18]  J. Copeland,et al.  Heart transplantation in patients with treated breast carcinoma. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  B. Griffith,et al.  Heart transplantation in patients with malignant disease. , 1990, The Journal of heart transplantation.

[20]  S. Hunt,et al.  Cardiac transplantation in patients with preexisting neoplastic diseases. , 1990, The American journal of cardiology.

[21]  J. Copeland,et al.  Selection of patients for cardiac transplantation. , 1987, Circulation.

[22]  Kazuo Yamada,et al.  Some Investigations on "Chain Doublet Theory" (Maegawa) : (2) On the Time Indicating the Arrival of Excitation Wave , 1954 .